The Polynucleotide Is Encapsidated Within A Bacteriophage, Bacteriophage Coat, Or Transducing Particle Patents (Class 435/472)
  • Patent number: 9822395
    Abstract: Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5? end tag and 3? end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites. In another embodiment, the nucleic acid sequence further comprises restriction endonuclease recognition sites specific for a rare cutting restriction endonuclease. Methods of using paired tags are also provided. In one embodiment, paired tags are used to characterize a nucleic acid sequence. In a particular embodiment, the nucleic acid sequence is a genome. In one embodiment, the characterization of a nucleic acid sequence is karyotyping. Alternatively, in another embodiment, the characterization of a nucleic acid sequence is mapping of the sequence.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 21, 2017
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Douglas Smith, Joel Malek, Kevin McKernan
  • Patent number: 9676641
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 13, 2017
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Publication number: 20150140038
    Abstract: Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 21, 2015
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: William R. Jacobs, JoAnn M. Tufariello
  • Publication number: 20150132263
    Abstract: The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Applicant: RADIANT GENOMICS, INC.
    Inventors: OLIVER LIU, JEFFREY KIM
  • Publication number: 20140221251
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD-2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporter's capacity to transport lipid IVA or in membrane protein YhjD. One or more genes (e.g., lpxL, lpxM, pagP, lpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Application
    Filed: September 7, 2012
    Publication date: August 7, 2014
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: David Bramhill, Uwe Mamat
  • Patent number: 8759087
    Abstract: A target internalized within a cell (and a binding member that specifically binds thereto) can be identified in an efficient manner by segregating (or substantially segregating) genetic material encoding the binding member from genetic material encoding a binding member that binds to a target that is not internalized. This can be achieved by employing a display library of binding members having a genotype/phenotype linkage via a non-fusion protein format, whereby genetic material encoding non-in-ternalized targets can be segregated (or substantially segregated) without lysing the cells. Internalized genetic material subsequently can be isolated and amplified.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: June 24, 2014
    Assignee: Morpho Sys AG
    Inventor: Markus Enzelberger
  • Publication number: 20140147890
    Abstract: The present invention relates to a genetically modified phage and use thereof in a method for producing a bio molecule of interest.
    Type: Application
    Filed: July 6, 2012
    Publication date: May 29, 2014
    Applicant: DELPHI GENETICS
    Inventor: Cedric Szpirer
  • Patent number: 8541229
    Abstract: Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: September 24, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Donald L. Court, Costantino Nina
  • Patent number: 8492343
    Abstract: There are provided a Kringle domain structure, comprising: inducing artificial mutations at amino acid residues except for conserved amino acid residues that are important to maintain the structural scaffold of a Kringle domain; and protein scaffold variants, based on the Kringle domain structure, which modulate the biological activities of a variety of target molecules derived from the protein scaffold library by specifically binding to the target molecules. Also, there is provided a method for constructing homo-/hetero-oligomers which allow multi-specificity binding to multiple targets by the tandem assembly monomeric Kringle domain variants using a linker. Additionally, there is provided a method for preparing multispecific monomers and multivalent monomers by grafting target-binding loops of a Kringle domain variant into non-binding loops of another Kringle domain variant with the same or different target binding specificity.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 23, 2013
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong-Sung Kim, Myung-Hee Kwon, Chang-Han Lee
  • Patent number: 8486418
    Abstract: The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: July 16, 2013
    Assignees: Merial Limited, University of Georgia Research Foundation, Inc.
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Egburt Mundt
  • Patent number: 8481056
    Abstract: Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 9, 2013
    Assignee: Vanderbilt University
    Inventors: Douglas S. Kernodle, Markian R. Bochan
  • Patent number: 8426187
    Abstract: Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: April 23, 2013
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Yariv Mazor
  • Publication number: 20130059334
    Abstract: The present invention generally relates to the production of industrially relevant quantities of selenoprotein enzymes in eukaryotic cell cultures. More specifically, the present invention generally relates to the production of such enzymes wherein one or more catalytic cysteine or serine residues are mutagenically replaced by selenocysteine.
    Type: Application
    Filed: June 28, 2012
    Publication date: March 7, 2013
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Richard Sayre, Hangsik Moon
  • Publication number: 20130040345
    Abstract: The invention relates to a host cell comprising at least four different heterologous polynucleotides chosen from the group of polynucleotides encoding cellulases, hemicellulases and pectinases, wherein the host cell is capable of producing the at least four different enzymes chosen from the group of cellulases, hemicellulases and pectinases, wherein the host cell is a filamentous fungus and is capable of secretion of the at least four different enzymes. This host cell can suitably be used for the production of an enzyme composition that can be used in a process for the saccharification of cellulosic material.
    Type: Application
    Filed: February 11, 2011
    Publication date: February 14, 2013
    Applicant: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Cornelis Maria Jacobus Sagt, Margot Elisabeth Francoise Schoonneveld-Bergmans, Robbertus Antonius Damveld
  • Publication number: 20130011898
    Abstract: The present invention relates to a genetically modified phage and use thereof in a method for producing a biomolecule of interest.
    Type: Application
    Filed: July 7, 2011
    Publication date: January 10, 2013
    Applicant: DELPHI GENETICS
    Inventor: Cédric Szpirer
  • Publication number: 20120329115
    Abstract: The present disclosure relates to methods of integrating recombinant polynucleotides into genomes of unicellular organisms. In particular, the present disclosure relates to the modified unicellular organisms that contain integrated recombinant polynucleotides in their genomes and methods for production of commodity chemicals by the use of such organisms.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 27, 2012
    Applicant: Bio Architecture Lab, Inc.
    Inventors: Christine SANTOS, Yasuo Yoshikuni
  • Patent number: 8337841
    Abstract: The present invention relates to methods of screening for commonly shared light chains, in which the method comprises the steps of (a) generating a host secreting the heavy chain of an antibody that binds to a desired antigen; (b) introducing an antibody light chain library into the host of step (a) to generate libraries presenting antibodies composed of the heavy chain and the light chains; (c) selecting a library presenting antibodies that bind specifically to the desired antigen of step (a); (d) introducing the library selected in step (c) into a host secreting the heavy chain of an antibody that binds to a desired antigen different from the antigen of step (a) to generate libraries that display antibodies composed of the heavy chains and light chains; and (e) selecting a library that displays antibodies that bind specifically to the desired antigen of step (d).
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: December 25, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Tetsuo Kojima
  • Publication number: 20110300538
    Abstract: The invention relates to CRISPR sequences found in bifidobacteria and their uses.
    Type: Application
    Filed: November 6, 2009
    Publication date: December 8, 2011
    Applicant: DANISCO A/S
    Inventors: Rodolph Barrangou, Philippe Horvath, Dennis A. Romero, Lindsay L. Traeger
  • Publication number: 20110224097
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporters capacity to transport Lipid IVA or in membrane protein YhjD. One or more genes (e.g., IpxL, IpxM, pagP, IpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Applicant: RESEARCH CORPORATION TECHNOLOGIES
    Inventors: David Bramhill, Uwe Mamat
  • Publication number: 20110053216
    Abstract: Disclosed is a modified photoautotrophic bacterium comprising genes of interest that are modified in terms of their expression and/or coding region sequence, wherein modification of the genes of interest increases production of a desired product in the bacterium relative to the amount of the desired product production in a photoautotrophic bacterium that is not modified with respect to the genes of interest.
    Type: Application
    Filed: October 19, 2007
    Publication date: March 3, 2011
    Inventor: Willem F. J. Vermaas
  • Publication number: 20100266627
    Abstract: Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., Mycobacterium avium subsp. paratuberculosis (Map), Map 10 or GFP-expressing Map K-10) using a phage-delivery system, and demonstrate high efficiency allelic exchange. Additional exemplary aspects provide non-naturally occurring slow-growing strains of mycobacteria (e.g., Map, M. bovis, M. tuberculosis) having at least one gene deletion (e.g., pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA_1, leuD, and leuC, and deletion mutants at the orthologous loci of two known virulence genes in pathogenic mycobacteria (relA and pknG) and one gene related to colony morphology and biofilm formation in fast growing mycobacteria (lsr2) were made. Further aspects provide novel vaccines comprising such deletion mutants, or portions thereof, and methods for making said vaccines. Yet further aspects provide methods for protecting a mammal from virulent Map, M.
    Type: Application
    Filed: July 14, 2008
    Publication date: October 21, 2010
    Applicant: WASHINGTON STATE UNIVERSITY
    Inventors: William C. Davis, Mary Jo Hamilton, John Dahl, Kun Taek Park
  • Patent number: 7691631
    Abstract: Methods are presented for enhancing the natural mutation rate of micro-organisms, particularly bacteria via a modified phosphate. The novel metabolite inhibits DNA repair mechanisms in vivo resulting in a 100-200 hundred fold increase in the mutation rate of bacteria. The method yields viable cells and allows for the continuous selection of incremental traits. The modified phosphate can also be used to randomly mutate specific genes. In particular, high rates of random mutagenesis can be readily achieved in vivo using recombinant DNA phage. The phage are amplified in mutator media containing the modified phosphate. The resultant phage can be further mutated by another round of infection and growth in mutator media. After two such rounds of amplification significant mutation rates are achieved such that each phage insert bears a novel mutation. The mutator media can also be used to mutagenize recombinant DNA plasmids in virtually any bacterial host.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: April 6, 2010
    Assignee: Frayne Consultants
    Inventor: Elizabeth Gay Frayne
  • Publication number: 20090298151
    Abstract: The disclosed invention relates to an isolated hydrogen gas producing microorganism, termed Enterobacter sp. SGT-T4™ and derivatives thereof. Compositions and methods comprising the disclosed microorganisms are also provided.
    Type: Application
    Filed: June 3, 2008
    Publication date: December 3, 2009
    Applicant: Dr. Elmar Schmid and James Gibson
    Inventors: Elmar Schmid, James Gibson
  • Publication number: 20090029433
    Abstract: The disclosed invention relates to an isolated hydrogen gas producing microorganism, termed Enterobacter sp. SGT 06-1™.
    Type: Application
    Filed: July 27, 2007
    Publication date: January 29, 2009
    Applicant: Dr. Elmar Schmid and James Gibson
    Inventors: Elmar Schmid, James Warner Gibson
  • Publication number: 20080287483
    Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.
    Type: Application
    Filed: May 29, 2008
    Publication date: November 20, 2008
    Inventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
  • Publication number: 20080213852
    Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms.
    Type: Application
    Filed: February 10, 2006
    Publication date: September 4, 2008
    Inventors: Bastian Chevreux, Anne F. Mayer, Anja Meury, Nigel J. Mouncey, Masako Shinjoh
  • Publication number: 20080153745
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.
    Type: Application
    Filed: December 1, 2005
    Publication date: June 26, 2008
    Applicant: Ambrx, In.
    Inventor: Feng Tian
  • Patent number: 7384640
    Abstract: A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus or parasite. In a particular embodiment, the amino acid 29 is histidine. The mutant cholera holotoxin may contain at least one additional mutation in the A subunit at a position other than amino acid 29. The antigenic composition may include a second adjuvant in addition to the mutant cholera holotoxin.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: June 10, 2008
    Assignees: Wyeth Holdings Corporation, The United States of America as represented by the Uniformed Services University of the Health Sciences
    Inventors: Randall K. Holmes, Michael G. Jobling, John H. Eldridge, Bruce A. Green, Gerald E. Hancock, Joel A. Peek
  • Publication number: 20080131932
    Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.
    Type: Application
    Filed: August 30, 2007
    Publication date: June 5, 2008
    Inventors: Hans De Nobel, David A. Estell, Wei Liu, Scott D. Power, Brian Schmidt, Huaming Wang
  • Publication number: 20080113417
    Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms.
    Type: Application
    Filed: February 10, 2006
    Publication date: May 15, 2008
    Inventors: Tatsuo Hoshino, Masako Shinjoh, Noribumi Tomiyama
  • Publication number: 20080113406
    Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.
    Type: Application
    Filed: May 14, 2007
    Publication date: May 15, 2008
    Applicant: AvidBiotics Corporation
    Inventors: David W. Martin, Andrew C. Jamieson, Dean M. Scholl, Steven R. Williams
  • Publication number: 20080113407
    Abstract: The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the unnatural amino acid sulfotyrosine into proteins produced in eubacterial host cells such as E. coli. The invention provides, for example but not limited to, novel orthogonal aminoacyl-tRNA synthetases, polynucleotides encoding the novel synthetase molecules, methods for identifying and making the novel synthetases, methods for producing proteins containing the unnatural amino acid sulfotyrosine and translation systems.
    Type: Application
    Filed: September 20, 2007
    Publication date: May 15, 2008
    Inventors: Chang C. Liu, Peter G. Schultz
  • Publication number: 20080113405
    Abstract: There are disclosed methods and compositions for gene expression and enhancement of protein production and/or accumulation. The invention provides gene-cassettes and methods of introducing the same into host cells for enhanced expression of target genes and production and/or accumulation of encoded proteins or peptides, or the like.
    Type: Application
    Filed: May 17, 2005
    Publication date: May 15, 2008
    Applicant: The Government of the United States of America as represented by the Secretary, Department of health
    Inventors: Sudeshna Kar, Sankar L. Adhya
  • Publication number: 20080107683
    Abstract: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo.
    Type: Application
    Filed: May 30, 2007
    Publication date: May 8, 2008
    Inventors: David Hone, John Fulkerson, Jerald C. Sadoff, David Onyabe, Michele Stone
  • Patent number: 7252942
    Abstract: The invention describes a method for the stacking of traits in a recombination proficient host using a phage transduction system. The method makes use of a nucleic acid integration cassette that has homology to a specific site on a host chromosome for the insertion of genetic elements and the stacking of traits. Repetition of the method results in the stacking of traits on a single genetic element.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: August 7, 2007
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Pierre E. Rouviere, Wonchul Suh
  • Publication number: 20070148636
    Abstract: Methods, compositions and kits are provided for labeling, copying and/or amplifying nucleic acids. The methods, compositions and kit can be used for a variety of applications, for example, genome-wide scanning applications such as CGH or location analysis.
    Type: Application
    Filed: December 23, 2005
    Publication date: June 28, 2007
    Inventors: Min-sun Song, Diane D. Ilsley
  • Patent number: 7135287
    Abstract: The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expressing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: November 14, 2006
    Assignees: Biosite, Inc., Medarex, Inc.
    Inventors: Nils Lonberg, Joe Buechler, Jeff Gray, Gunars Valkirs
  • Patent number: 7118915
    Abstract: A method for generating a mutein of human apolipoprotein D having detectable affinity to a given non-natural ligand of apolipoprotein D is disclosed, which comprises the steps of: (a) subjecting the apolipoprotein D to mutagenesis at the sequence positions 34 to 38, 60, 62 to 66, 68, 89 to 93, 115, 117 to 121, and 123 resulting in a plurality of muteins of apolipoprotein D; and (b) enriching resulting muteins having binding affinity for a given ligand from the plurality of muteins by selection, and/or isolating said mutein. Muteins of apolipoprotein D obtainable by this method are also disclosed.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: October 10, 2006
    Assignee: Pieris Proteolab AG
    Inventors: Martin Vogt, Arne Skerra
  • Patent number: 7112435
    Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: September 26, 2006
    Assignee: Ambit Biosciences Corporation
    Inventors: Pietro Ciceri, Patrick Parvis Zarrinkar, Daniel Kelly Treiber, David J. Lockhart
  • Patent number: 7049135
    Abstract: The present invention relates to methods for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex by screening for polyphage particles. Furthermore, the invention relates to products and uses thereof for the identification of nucleic acid sequences in accordance with the present invention.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: May 23, 2006
    Assignee: Morphosys AG
    Inventors: Fritz Rudert, Liming Ge, Vic Ilag
  • Patent number: 7033607
    Abstract: A polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 25, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Vladimir S. Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jon A. Wolff, David B. Rozema, Sean D. Monahan
  • Patent number: 7022336
    Abstract: The invention provides methods of attaching proteins to lipidic microparticles with efficiencies of at least 77%. The proteins are attached to linker molecules comprising a hydrophilic domain and a hydrophobic domain. The proteins can be antibodies, antibody fragments, hormones, growth factors, enzymes, or nucleic acid binding proteins, or other proteins. The proteins can be chemically conjugated to the linker molecules, or they can be fused to the linker molecules by recombinant techniques.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: April 4, 2006
    Assignee: The Regents of the University of California
    Inventors: Demetrios Papahadjopoulos, Keelung Hong, Weiwen Zheng, Dmitri B. Kirpotin
  • Patent number: 6982087
    Abstract: Provided herein are alphavirus vectors derived from South African Arbovirus No. 86 (S.A.AR86) comprising attenuating mutations and methods of making the same. Also provided are improved viral vectors and helper constructs comprising a S.A.AR86 capsid enhancer sequence. The present invention also provides S.A.AR86 replicon and helper constructs comprising an alphavirus capsid enhancer sequence. Further provided are methods of administering an alphavirus vector comprising a heterologous nucleotide sequence (preferably encoding an immunogen or a therapeutic polypeptide) according to the invention to a cell or subject. In preferred embodiments, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: January 3, 2006
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Robert E. Johnston, Mark T. Heise, Dennis Simpson
  • Patent number: 6962810
    Abstract: More efficient transfer of genes into host cells or embryos to transform the cells or embryos is facilitated by transposition vectors using the minimal amount of nucleotide sequences in the transposon piggyBac required for gene transfer. The transformed cells or embryos may be developed into transgenic organisms.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: November 8, 2005
    Assignee: University of Notre Dame du Lac
    Inventors: Malcolm J. Fraser, Xu Li
  • Patent number: 6943012
    Abstract: A helper dependent adenoviral vector system is provided. The subject helper dependent adenoviral vector system is made up of: (1) a “gutless” adenoviral vector that include cis-acting human stuffer DNA that provides for in vivo long term, high level expression of a coding sequence present on the vector; (2) an adenoviral helper vector that is characterized by having an adenoviral genome region flanked by recombinase recognition sites, where the helper vectors further include a non-mammalian endonuclease recognition site positioned outside of the adenoviral genome region; and (3) a mammalian cell that expresses the corresponding recombinase and endonuclease, as well as the adenoviral preterminal and polymerase proteins. Also provided are methods of using the subject systems to produce virions having the subject helper dependent adenoviral vectors encapsulated in an adenoviral capsid. In addition, kits for use in practicing the subject methods are provided.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: September 13, 2005
    Assignee: The Board of Trustees of the Leland Stanford Junor University
    Inventors: Anja Ehrhardt, Mark A. Kay
  • Patent number: 6919091
    Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: July 19, 2005
    Assignee: Mirus Corporation
    Inventors: Vladimir S. Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jon A. Wolff, David B. Rozema, Sean D. Monahan
  • Patent number: 6884623
    Abstract: The invention relates to assembled particles of a plant virus containing a foreign peptide insert in the coat protein of the virus. The site of the insert is preferably free from direct sequence repeats flanking the insert. The invention relates to a method of production of the particles and their use, in particular in vaccines.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: April 26, 2005
    Assignee: The Dow Chemical Company
    Inventors: George P. Lomonossoff, John E. Johnson, Mary Bendig, Tim Jones, Marian Longstaff
  • Patent number: 6881576
    Abstract: A polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 19, 2005
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker, Vladimir S. Trubetskoy
  • Publication number: 20040248101
    Abstract: A selectively inducible, single-stranded DNA (ssDNA) expression library, a method for constructing a ssDNA expression library, a method for screening ssDNA using the expression library, and a method for identifying ssDNA molecules that switch on or off bacterial gene(s) related to cell growth and toxin production and secretion. The screening library is used to, among other things, identify ODNs effective in stopping bacterial growth, killing bacteria or preventing bacteria from synthesizing and secreting their toxins is the focus of the present invention and/or to discover ODNs effective in eukaryotic (e.g., mammalian) cells for targeted gene down regulation. The library is also useful for identifying ssDNAs or ODNs that are used as therapeutic antibacterial reagents, for identifying essential bacterial genes that can serve as targets for antibiotic discovery, and for providing a method for treatment of bacterial infections.
    Type: Application
    Filed: June 3, 2003
    Publication date: December 9, 2004
    Applicant: CytoGenix, Inc.
    Inventors: Yin Chen, Xin Xing Tan
  • Publication number: 20040219169
    Abstract: The present application generally discloses delivery of an agent which can be therapeutic or prophylactic and, more particularly, the preparation and use of attenuated bacteria, such as Salmonella, containing a bacteriophage in which the genome of the bacteriophage has been modified to encode for a gene product of interest, eg., an antigen or an anti-tumor protein. The bacteria functions as a vector for delivering the bacteriophage encoded gene product of interest to an appropriate site of action, e.g., the site of a solid tumor.
    Type: Application
    Filed: March 1, 2004
    Publication date: November 4, 2004
    Inventors: David G. Bermudes, Ivan C. King, Caroline A. Clairmont